Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1

Journal of Neuro-Oncology

Volumn 42, Issue 2, 1999, Pages 95-102

  Osmak, Maja ^a   Vrhovec, Ivan ^b   Škrk, Janez ^b  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Cisplatin; Drug resistance; Glioblastoma cells; Plasminogen activator; Plasminogen activator inhibitor

Indexed keywords

CHLORAMBUCIL; CISPLATIN; CYTOSTATIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; VINCRISTINE; VINCRISTINE SULFATE;

ARTICLE; CANCER CELL CULTURE; COLORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DIVISION; CELL SURVIVAL; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETOPOSIDE; GLIOBLASTOMA; HUMANS; KINETICS; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR; VINCRISTINE;

EID: 0032997148     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006125629887     Document Type: Article

References (34)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991
2. Laiho M, Keski-Oja J: Growth factors in the regulation of pericellular proteolysis: areview. Cancer Res 49: 2533-2553, 1989
3. Boyd D: Invasion and metastasis. Cancer Metast Rev 15: 77-89, 1996
4. Schmitt M, Janicke F, Graeff H: Tumor-associated proteases. Fibrinolysis 6: 3-26, 1992
5. Rijken DC: Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Bailliere's Clinical Haematology 8: 291-312, 1995
6. Yu H, Schultz R: Relationship between secreted urokinase plasminogen activator actitvity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 50: 7623-7633, 1991
7. Achbarou A, Kaiser S, Tremblay G, Ste-Marie L, Brodt P, Glotzman D, Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo Cancer Res 54: 2372-2377, 1994
8. Hsu DW, Efird JT, Hedleywbyte ET: Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147: 114-123, 1995
9. Duffy MJ: Proteases as prognostic markers in cancer. Clinic Cancer Res 2: 613-618, 1996
10. Kruithof EK: Plasminogen activator inhibitors - a review. Enzyme 40: 113-121, 1988
11. Pappot H, Gardsvoll H, Romer J, Navrsted Pedersen A, Grondahl-Hansen J, Pyke C, Bruenner N: Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol. Chem. Hoppe-Seyler, 376:259-267, 1995
12. Ossowski L, Reich B: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-619, 1983
13. Cajot JF, Bamat J, Bergonzelli GE: Plasminogen-activator inhibitor type 1 is potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA 87: 6939-6943, 1990
14. Montgomery AMP, De Clerck YA, Langley KE, Reisfeld RA, Mueller BM: Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res 53: 693-700, 1993
15. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T: Cisplatin resistance in human cancers. Pharm Ther 52: 385-406, 1991
16. Calsou P, Salles B: Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. Cancer Chemother Pharmacol 32: 85-89, 1993
17. Gately DP, Howell SB: Cellular accumulation of the anti-cancer agent cisplatin: a review. Br J Cancer 67: 1171-1179, 1993
18. Andrews PA: Mechanisms of aquired resistance to cisplatin. In: Goldstien LJ, Ozols RF (eds) Anticancer Drug Resistance: Advances in Molecular and Clinical Research. Kluwer Academic Publishers, Norwell, 1994, pp 217-247
19. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Chirsten RD, Haas M, MacLeod CL, Howell SB: In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57: 1841-1845, 1997
20. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer aborgates FAS/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic radiation. J Clin Invest 6: 2633-2643, 1995
21. Nagane M, Levitzki A, Gazit, A, Cavenee WK, Huang HJS: Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of bcl-x-1-and caspase-3-like proteases. Proc Nad Acad Sci USA 95: 5724-5729, 1998
22. Dorige O, Turla ST, Lebedeva S, Gjerset RA: Sensitisation of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg 88: 535-540, 1998
23. Osmak M: Molecular alterations induced in drug-resistant cells. Radiol Oncol 32: 19-33, 1998
24. Osmak M, Nikšić, Brozović A, Vrhovec I, Škrk J: Molecular alterations induced in drug resistant cells. Period Biol 100 (Supp 1): 48-49, 1998
25. Osmak M, Miljanić S, Kapitanović S: Low doses of γ-rays can induce the expression of mdr gene. Mutat Res 324: 35-41, 1994
26. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976
27. Osmak M, Eljuga D: The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin. Res Exptl Med 193: 389-396
28. Beketić-Orešković L, Osmak M: Human larynx carcinoma cells resistant to cis-diamminedichloroplatinum(II): Cross-resistance patterns. Neoplasma 41: 171-76, 1994
29. Dano K, Dabelsteen E, Nielsen LS, Kaltoft K, Wilson EL, Zeuthen J: Plasminogen activating enzyme in cultured glioblastoma cells. J Histochem Cytochem 30: 1165-1170, 1982
30. Gross JL Behrens DL, Mullins DE, Kornblith PL, Dexter DL: Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. Cancer Res 48: 291-296, 1988
31. Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R: Elevated levels of Mr 92000 type IV collagenase in human brain tumors. Cancer Res 53: 2208-2211, 1993
32. Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson GL, Rao JS: Overexpression and localisation of cathepsin B during the progression of human glioblastomas. Clin Exp Metastasis 13: 49-56, 1995
33. Sivaparvathi M, Sawaya R, Chintala SK, Go Y, Gokaslan ZL, Rao JS: Expression of cathepsin D during the progression of human gliomas. Neurosci Letters 208: 171-174, 1996
34. Quax PHA, Van Leeuwen RTJ, Verspaget HW, Verheijen JH: Protein and messenger RNA levels of plasminogen activators and inhbitors analysed in 22 human tumor cell lines. Cancer Res 50: 1488-1494, 1990